Lead Product(s) : CS-002
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Complex Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)
Details : CS-002 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Canities.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2025
Lead Product(s) : CS-002
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Complex Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RiboX Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001
Details : RXRG001 is an AQP1 modulator, circular RNA, which is currently being evaluated for the treatment of patients with radiation-induced-xerostomia (RIX) and hyposalivation.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
Details : RXRG001 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : RXRG001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing
Details : Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2023
Lead Product(s) : AAV-AQP1
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Sanofi
Deal Size : $30.0 million
Deal Type : Financing
Lead Product(s) : Cannabidiol
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : CB21 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
CBD Effects on Periodontal Health of Patients With Chronic Periodontitis
Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Chronic Periodontitis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : CB21 Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KH001
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients
Details : KH001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dentin Sensitivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : KH001
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMY-101
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis
Details : AMY-101 is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gingivitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 03, 2018
Lead Product(s) : AMY-101
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PerioSept (Taurolidine) is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Periodontitis.
Product Name : PerioSept
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 10, 2014
Lead Product(s) : Taurolidine
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mighteaflow
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Green Tea Lozenges for the Management of Dry Mouth
Details : Mighteaflow is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Xerostomia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 24, 2012
Lead Product(s) : Mighteaflow
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Bone Mesenchymal Stem Cell
Therapeutic Area : Dental and Oral Health
Study Phase : Phase I/ Phase II
Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)
Details : Autologous Bone Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Maxillary Cyst.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 08, 2011
Lead Product(s) : Autologous Bone Mesenchymal Stem Cell
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase I/ Phase II
Sponsor : Sanidad de Castilla y León | University of Valladolid | CRMR Castilla y León | Citospin
Deal Size : Inapplicable
Deal Type : Inapplicable